Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new two-step method promises to revolutionize targeted cancer drug development by ...

Cancer antigens targeted by drug conjugates are restricted to the few membrane receptors (such as HER2 and TROP2) that ...

The very first antibody-drug conjugates (ADCs) to enter clinical evaluation sought to improve the therapeutic index of approved anti-cancer drugs, such as doxorubicin and vinblastine, by linking them ...

Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Poster sessions to highlight encouraging preclinical data for NEOK001 (ABL206), a first-in-class bispecific ADC targeting B7-H3 and ROR1-expressing solid tumors, and NEOK002 (ABL209), a bispecific ADC ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

Antibody drug conjugates bring a targeted approach to the treatment of many types of cancer, but there’s still room for improving this class of therapies. This week, two startups revealed how they aim ...

A two-antibody click-chemistry strategy improves targeted chemotherapy delivery to resistant HER2- and EGFR-positive tumors, boosting tumor control in mice.

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering. This report ...